In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Precigen (PGEN – Research Report), with a price target of $10.00. The company's shares closed last Tuesday at $2.16, close to its 52-week low of $1.91. According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 11.0% and a 39.6% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Cellectar Biosciences, Harpoon Therapeutics, and Corcept Therapeutics. Currently, the analyst consensus on Precigen is a Strong Buy with an average price target of $13.33, a 522.9% upside from current levels.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-precigens-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral